143 related articles for article (PubMed ID: 38029652)
21. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
22. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP; Roque DM; Santin AD
Mol Diagn Ther; 2013 Apr; 17(2):85-99. PubMed ID: 23529353
[TBL] [Abstract][Full Text] [Related]
23. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
24. p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ; McCluggage WG
Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
[TBL] [Abstract][Full Text] [Related]
25. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
Growdon WB; Groeneweg J; Byron V; DiGloria C; Borger DR; Tambouret R; Foster R; Chenna A; Sperinde J; Winslow J; Rueda BR
Gynecol Oncol; 2015 Apr; 137(1):160-6. PubMed ID: 25602714
[TBL] [Abstract][Full Text] [Related]
26. Molecular evidence for a clonal relationship between synchronous uterine endometrioid carcinoma and ovarian clear cell carcinoma: a new example of "precursor escape"?
Weng CH; Wu RC; Chen SJ; Chen HC; Tan KT; Lee YS; Huang SS; Yang LY; Wang CJ; Chou HH; Chao AS; Chao A; Lai CH
J Mol Med (Berl); 2021 Jul; 99(7):959-966. PubMed ID: 33768299
[TBL] [Abstract][Full Text] [Related]
27. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix.
Mitra AB; Murty VV; Pratap M; Sodhani P; Chaganti RS
Cancer Res; 1994 Feb; 54(3):637-9. PubMed ID: 7905784
[TBL] [Abstract][Full Text] [Related]
28. Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations.
Boyd J; Risinger JI
Mol Carcinog; 1991; 4(3):189-95. PubMed ID: 2064724
[TBL] [Abstract][Full Text] [Related]
29. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.
Diver EJ; Foster R; Rueda BR; Growdon WB
Oncologist; 2015 Sep; 20(9):1058-68. PubMed ID: 26099744
[TBL] [Abstract][Full Text] [Related]
30. Molecular analysis in endometrial cancer.
Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
[TBL] [Abstract][Full Text] [Related]
31. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence.
Conesa-Zamora P; Torres-Moreno D; Isaac MA; Pérez-Guillermo M
Exp Mol Pathol; 2013 Oct; 95(2):151-5. PubMed ID: 23827764
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
33. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
34. Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists.
Rabban JT; Gilks CB; Malpica A; Matias-Guiu X; Mittal K; Mutter GL; Oliva E; Parkash V; Ronnett BM; Staats P; Stewart CJR; McCluggage WG
Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S25-S39. PubMed ID: 30550482
[TBL] [Abstract][Full Text] [Related]
35. Incidence and effects on mortality of venous thromboembolism in elderly women with endometrial cancer.
Rauh-Hain JA; Hariton E; Clemmer J; Clark RM; Hall T; Boruta DM; Schorge JO; Del Carmen MG
Obstet Gynecol; 2015 Jun; 125(6):1362-1370. PubMed ID: 26000507
[TBL] [Abstract][Full Text] [Related]
36. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
37. Molecular staging of gynecological cancer: What is the future?
Binder PS; Prat J; Mutch DG
Best Pract Res Clin Obstet Gynaecol; 2015 Aug; 29(6):776-89. PubMed ID: 25934522
[TBL] [Abstract][Full Text] [Related]
38. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
[TBL] [Abstract][Full Text] [Related]
39. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL; Banet N; Buza N
Pathology; 2023 Feb; 55(1):8-18. PubMed ID: 36503635
[TBL] [Abstract][Full Text] [Related]
40. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
